FDA OKs First Cell Therapy for Severe Aplastic Anemia

The approval marks the second indication for omidubicel, following its 2023 nod for patients with hematologic malignancies set to undergo cord blood transplantation.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-oks-first-cell-therapy-severe-aplastic-anemia-2025a1000yfl?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension